# A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.

> **NCT00240032** · PHASE4 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 80 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** glatiramer acetate injection with oral cetirizine hydrochloride
- **DRUG:** glatiramer acetate with placebo

## Key facts

- **NCT ID:** NCT00240032
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2006-06
- **Final completion:** 2006-07
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2011-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00240032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00240032, "A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00240032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*